JP2024514293A - 前立腺がんの診断方法 - Google Patents
前立腺がんの診断方法 Download PDFInfo
- Publication number
- JP2024514293A JP2024514293A JP2023560269A JP2023560269A JP2024514293A JP 2024514293 A JP2024514293 A JP 2024514293A JP 2023560269 A JP2023560269 A JP 2023560269A JP 2023560269 A JP2023560269 A JP 2023560269A JP 2024514293 A JP2024514293 A JP 2024514293A
- Authority
- JP
- Japan
- Prior art keywords
- psma
- pet
- radioligand
- group
- contrast agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/121—Solutions, i.e. homogeneous liquid formulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21305432 | 2021-04-02 | ||
| EP21305432.3 | 2021-04-02 | ||
| PCT/EP2022/058754 WO2022207906A1 (en) | 2021-04-02 | 2022-04-01 | Diagnostic methods of prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514293A true JP2024514293A (ja) | 2024-04-01 |
| JP2024514293A5 JP2024514293A5 (cg-RX-API-DMAC7.html) | 2025-04-10 |
Family
ID=75588163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560269A Pending JP2024514293A (ja) | 2021-04-02 | 2022-04-01 | 前立腺がんの診断方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240181092A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4313175A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024514293A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230165761A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117120100A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3215723A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL307381A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202304531A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022207906A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3972627A4 (en) | 2019-05-20 | 2023-06-21 | Endocyte, Inc. | Methods for preparing psma conjugates |
| WO2022106629A1 (en) | 2020-11-19 | 2022-05-27 | Novartis Ag | Synthesis of prostate specific membrane antigen (psma) ligands |
| CN120897762A (zh) * | 2023-04-12 | 2025-11-04 | 康奈尔大学 | 用于治疗癌症的放射治疗缀合物 |
| WO2026027442A1 (en) | 2024-08-01 | 2026-02-05 | Novartis Ag | Synthesis of a precursor of radiopharmaceutical products |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014143736A1 (en) * | 2013-03-15 | 2014-09-18 | Cancer Targeted Technology Llc | 18f-labeled psma-targeted pet imaging agents |
| JP2020528461A (ja) * | 2017-07-28 | 2020-09-24 | テクニシェ ユニバーシタット ミュンヘン | デュアルモードの放射性トレーサーおよび療法剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013173630A1 (en) * | 2012-05-16 | 2013-11-21 | Cancer Targeted Technology, Llc | Formulation of radiopharmaceuticals containing multiple acidic groups |
| WO2013173583A1 (en) | 2012-05-16 | 2013-11-21 | Cancer Targeted Technology, Llc | Psma inhibitors |
-
2022
- 2022-04-01 CA CA3215723A patent/CA3215723A1/en active Pending
- 2022-04-01 WO PCT/EP2022/058754 patent/WO2022207906A1/en not_active Ceased
- 2022-04-01 KR KR1020237032903A patent/KR20230165761A/ko active Pending
- 2022-04-01 IL IL307381A patent/IL307381A/en unknown
- 2022-04-01 EP EP22720606.7A patent/EP4313175A1/en active Pending
- 2022-04-01 JP JP2023560269A patent/JP2024514293A/ja active Pending
- 2022-04-01 TW TW111112920A patent/TW202304531A/zh unknown
- 2022-04-01 CN CN202280026305.2A patent/CN117120100A/zh active Pending
- 2022-04-01 US US18/552,760 patent/US20240181092A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014143736A1 (en) * | 2013-03-15 | 2014-09-18 | Cancer Targeted Technology Llc | 18f-labeled psma-targeted pet imaging agents |
| JP2020528461A (ja) * | 2017-07-28 | 2020-09-24 | テクニシェ ユニバーシタット ミュンヘン | デュアルモードの放射性トレーサーおよび療法剤 |
Non-Patent Citations (2)
| Title |
|---|
| JOURNAL OF NUCLEAR MEDICINE, vol. vol. 58 (suppl. 1), JPN6026011215, May 2017 (2017-05-01), pages 733, ISSN: 0005822573 * |
| JOURNAL OF NUCLEAR MEDICINE, vol. vol. 60(7), JPN6026011216, 21 November 2018 (2018-11-21), pages 910 - 916, ISSN: 0005822574 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202304531A (zh) | 2023-02-01 |
| CN117120100A (zh) | 2023-11-24 |
| WO2022207906A1 (en) | 2022-10-06 |
| IL307381A (en) | 2023-11-01 |
| KR20230165761A (ko) | 2023-12-05 |
| CA3215723A1 (en) | 2022-10-06 |
| EP4313175A1 (en) | 2024-02-07 |
| US20240181092A1 (en) | 2024-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lohrmann et al. | Retooling a blood-based biomarker: phase I assessment of the high-affinity CA19-9 antibody HuMab-5B1 for immuno-PET imaging of pancreatic cancer | |
| EP4313175A1 (en) | Diagnostic methods of prostate cancer | |
| Granov et al. | Positron emission tomography | |
| Sinnes et al. | Instant kit preparation of 68Ga-radiopharmaceuticals via the hybrid chelator DATA: clinical translation of [68Ga] Ga-DATA-TOC | |
| US20250025584A1 (en) | Radiopharmaceutical treatment methods and use | |
| US20250269073A1 (en) | [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof | |
| Wu et al. | First-in-human evaluation of [211At] YF2 in patients with metastatic castration-resistant prostate cancer | |
| Dietlein et al. | A novel 18F-labeled PSMA ligand for PET/CT imaging of prostate cancer patients: First-in-man observational study and clinical experience with 18F-JK-PSMA-7 during the first year of application | |
| AU2018381046B2 (en) | Radiolabeled progastrin in cancer diagnosis | |
| Baum et al. | Third theranostics world congress on gallium-68 and PRRT: abstracts | |
| Rudd | Looking backward to move forward: A chemist’s perspective on the future of radiopharmaceuticals | |
| O'Brien et al. | Managing a high-specific-activity iobenguane therapy clinic: from operations to reimbursement | |
| US20250032651A1 (en) | [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof | |
| US20240042067A1 (en) | [177lu] lutetium-psma i&t composition, kit, method of making, and method of using thereof | |
| Lucignani | Non-standard PET radionuclides: time to get ready for new clinical PET strategies | |
| Eckelman | Review of new clinical applications of radiometal labeled radiopharmaceuticals | |
| Elison et al. | ANZSNM ASM 2021 POSTER PRESENTATIONS | |
| PART | growth factor (anti-VEGF), antiepidermal growth | |
| Bailey | Advancing targeting radiopharmaceuticals for theranostic applications | |
| US20160193372A1 (en) | Methods of identifying surrogate imaging agents for alpha emitter radiopharmaceuticals and their use in treatment of disease | |
| Rose et al. | Imaging with radionuclides | |
| Bhusari et al. | Lu-177-Herceptin: A Potential Radioimmunoconjugate for Treatment of HER2 Metastatic Breast Cancer | |
| Lam | Translation and Development of Molecular Imaging Probes for Detecting Response of Breast Cancer to Trastuzumab | |
| Witkowska-Patena et al. | 18F-PSMA-1007-a breakthrough in PET/CT prostate cancer imaging? A systematic review | |
| Györke et al. | Sapital standardisation of RCBF-SPECT in early dementia patients and healthy control subjects |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20240229 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240229 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250401 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250401 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260319 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260324 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260604 |